These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 2100567)

  • 21. CYFRA 8/18 in head and neck cancer.
    Maass JD; Niemann AM; Lippert BM; Gottschlich S; Folz BJ; Werner JA
    Anticancer Res; 1999; 19(4A):2699-701. PubMed ID: 10470223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum nitric oxide levels in patients with head and neck squamous cell carcinoma.
    Kizilay A; Kalcioğlu MT; Ozuğurlu F; Ozyurt H; Aladağ I; Ozturan O; Akyol O
    Kulak Burun Bogaz Ihtis Derg; 2007; 17(3):148-51. PubMed ID: 17873505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer.
    Wollenberg B; Jan V; Schmit UM; Hofmann K; Stieber P; Fateh-Moghadam A
    Anticancer Res; 1996; 16(5B):3117-24. PubMed ID: 8920778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Squamous cell carcinoma antigen levels in patients with laryngeal cancer].
    Polberg K; Stepulak A; Stryjecka-Zimmer M; Kupisz K; Zawiślak J
    Pol Merkur Lekarski; 2005 Sep; 19(111):375-6. PubMed ID: 16358876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma.
    Van Hal NL; Van Dongen GA; Ten Brink CB; Heider KH; Rech-Weichselbraun I; Snow GB; Brakenhoff RH
    Clin Cancer Res; 1999 Nov; 5(11):3534-41. PubMed ID: 10589769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor markers and lymphatic metastasis in head and neck cancer patients.
    Büntzel J; Hornig A; Glatzel M; Micke O; Bruns F; Schäfer U; Fröhlich D
    Anticancer Res; 2005; 25(3A):1539-42. PubMed ID: 16033056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The significance of Tenascin-C serum level as tumor marker in squamous cell carcinoma of the head and neck.
    Pauli C; Stieber P; Schmitt UM; Andratschke M; Hoffmann K; Wollenberg B
    Anticancer Res; 2002; 22(5):3093-7. PubMed ID: 12530049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical protocols for the application of tests for circulating tumor markers.
    Bombardieri E; Buraggi GL
    Ann Ist Super Sanita; 1991; 27(3):541-6. PubMed ID: 1809077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling.
    Linkov F; Lisovich A; Yurkovetsky Z; Marrangoni A; Velikokhatnaya L; Nolen B; Winans M; Bigbee W; Siegfried J; Lokshin A; Ferris RL
    Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):102-7. PubMed ID: 17220337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of glycoproteins as prognosticators in head and neck malignancy.
    Bathi RJ; Nandimath K; Kannan N; Shetty P
    Indian J Dent Res; 2001; 12(2):93-9. PubMed ID: 11665403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Tumor markers in uterine cancers].
    Fukasawa I; Kousaka N; Kun Z; Inaba N
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):333-40. PubMed ID: 11865645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Squamous cell carcinoma antigen for monitoring patients with head neoplasm].
    Adamiak G; Ligeziński A; Jurkiewicz D; Hermanowski M; Konieczna M
    Pol Merkur Lekarski; 1999 Nov; 7(41):221-3. PubMed ID: 10680455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 autoantibodies as tumor marker in head and neck squamous cell cancer.
    Gottschlich S; Hoffmann M; Maass JD; Görörgh T; Buhmann V; Hoffmann-Fazel A; Rudert H; Maune S
    Anticancer Res; 2003; 23(2A):913-5. PubMed ID: 12820322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer.
    Kuropkat C; Plehn S; Herz U; Dünne AA; Renz H; Werner JA
    Anticancer Res; 2002; 22(4):2221-7. PubMed ID: 12174907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical value of squamous cell carcinoma antigen in patients irradiated for locally advanced cancer of the head and neck.
    Micke O; Bruns F; Schäfer U; Horst E; Büntzel J; Willich N
    Anticancer Res; 2003; 23(2A):907-11. PubMed ID: 12820321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Head and neck squamous cell carcinoma: measurement of plasma parathyroid hormone-related protein and serum and urine calcium concentrations.
    Sellers RS; Schuller DE; Sharma PK; Tannehill-Gregg SH; Capen CC; Rosol TJ
    Otolaryngol Head Neck Surg; 2000 Nov; 123(5):558-62. PubMed ID: 11077340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck.
    Sauter ER; Nesbit M; Watson JC; Klein-Szanto A; Litwin S; Herlyn M
    Clin Cancer Res; 1999 Apr; 5(4):775-82. PubMed ID: 10213212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenes, molecular biology and the head and neck surgeon.
    Irish JC
    J Otolaryngol; 1992 Dec; 21 Suppl 3():1-20. PubMed ID: 1289578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular diagnostics for head and neck pathology.
    Bilodeau E; Alawi F; Costello BJ; Prasad JL
    Oral Maxillofac Surg Clin North Am; 2010 Feb; 22(1):183-94. PubMed ID: 20159486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.